In vivo evaluation of lag screw fixation of sacroiliac luxation/fracture: A comparative prospective study
Study Investigators
- Loic M. Dejardin, DVM, MS, DACVS, DECVS
- Karen L. Perry, BVM&S, MRCVS, DECVS
Enrollment Criteria and Benefits
- Patients that have sustained sacroiliac luxations and/or fractures (SIL/F)
- Pre and post-op CT costs covered following enrollment
- Follow up six-month examination and radiograph costs covered
Background
SIL/F repair is usually performed using lag screw fixation and can be achieved via:
- ORIF (Open Reduction and Internal Fixation)
- C-MIO (Conventional Minimally Invasive Osteosynthesis)
- N-MIO (Novel MIO)
What are ORIF, C-MIO, and N-MIO repairs?
Limitations of ORIF include extensive soft tissue dissection as well as suboptimal screw orientation within the sacral body. Screw orientation away from the so called “safe sacral implantation corridor” results in poor fixation, neurological impairment and implant loosening.
While screw orientation is improved with MIO, exposure of both the patient and surgical team to intraoperative radiation remains a concern with C-MIO. The proposed benefits of N-MIO over ORIF and C-MIO include maintaining the minimally invasive approach and improved sacral screw orientation whilst also reducing surgical time, patient morbidity and exposure to radiation.
This is achieved by relying on table-bound articulated arms rather than the surgeon to
- Achieve and maintain SIL/F reduction
- Align and maintain a targeting device over the sacrum
While all three approaches have been successfully performed at MSU, comparative evaluation is needed to support objective recommendations regarding efficacy and safety.
Therefore, we are in search of patients who meet the following criteria:
- Any canine and feline patients who have sustained a SIL/F regardless of displacement
- Uni or bilateral SIL/F with or without concomitant orthopedic and soft tissue injuries
All surgeries will be performed by Dr. Déjardin and Dr. Perry. Should you see a patient with SIL/F, please contact Dr. Dejardin at (517) 282-2181 (cell) to discuss enrollment in the study.